International Journal of Scientific & Engineering Research Volume 9, Issue 8, August ISSN
|
|
- Suzan Bell
- 5 years ago
- Views:
Transcription
1 International Journal of Scientific & Engineering Research Volume 9, Issue 8, August Safety and efficiency of a topical corticosteroid in psoriasis Bahni Mohammed Ali Asiri Abstract: The aim of this study was to perform a literature review to prepare for evidence-based recommendations on the efficacy of topical corticosteroids in psoriasis including treatment modalities to induce remission and prevent recurrence. We conducted an electronic search through online databases such; Medline, and Embase, for studies concerning efficacy of topical corticosteroids in psoriasis. Topical CS are an essential component of the psoriasis therapeutic apparatus. The outcomes of this existing review indicate that topical steroids in the therapy of adult psoriasis are extremely safe if utilized according to the guidelines. The indication of topical steroids for psoriasis should be limited to mild or moderate psoriasis with much less compared to 10% of body surface location impacted making use of a 4-week daily therapy. The effectiveness of treatment should be assessed within 1-2 months after the preliminary prescription. Introduction: Psoriasis is a chronic inflammatory disease affecting 1-2% of the populace around the world [1].Medically, psoriasis presents as well-demarcated, increased, erythematous, scaly plaques predominantly impacting the scalp, trunk and extensor surface areas; nevertheless, anybody site can additionally be entailed. Psoriasis is an emotionally incapacitating condition and can have
2 International Journal of Scientific & Engineering Research Volume 9, Issue 8, August extensive effect on patients' top quality of life despite the degree of body surface area (BSA) participation. Mild-to-moderate psoriasis impacts ~ 80% of the overall psoriasis population around the world [2]. Topical medicine is typically made use of as very first line of treatment in moderate psoriasis yet could also be used with phototherapy, systemic or biologic treatments for moderate-to-severe psoriasis. Topical steroids are used for more compared to 50 years for the treatment of mild-tomoderate adult plaque psoriasis. Their short-term efficiency differs from 5% to 90% relying on molecule and solution [3].Systemic results complying with application of topical steroids belong to systemic absorption of the product. Exogenous glucocorticoids have a suppressive impact on hypothalamic corticotropin-releasing hormone and pituitary adrenocorticotropic hormone (ACTH). With extended use corticosteroids, reductions of the hypothalamic-pituitary axis (HPA) and adrenal insufficiency by adrenal glands degeneration could take place, and it could take months to recoup fully after discontinuation of exogenous glucocorticoids.the boosted degree of glucocorticoids in the blood can additionally cause professional signs of hypercorticism (iatrogenic Cushing disorder) such as arterial hypertension, diabetes, anxiety or irritation, faciotroncular obesity, buffalo neck, hirsutism, vulnerable skin, pink striae and telangiectasia. Systemic absorption of topical steroids differs according to age, skin lesions place and extension of the illness. Furthermore, duration of use, strength, formulation and molecule used could additionally contribute [4].In addition, the function of particular skin conditions requires to be taken into consideration in the capacity for topically applied steroids to produce negative effects. Without a doubt, conditions connected with skin obstacle damages such as atopic dermatitis or Netherton condition have been related to enhanced percutaneous absorption of topical corticosteroids and HPA axis reductions. This remains unclear in the situation of plaque psoriasis
3 International Journal of Scientific & Engineering Research Volume 9, Issue 8, August which is to be taken into consideration as a chronic skin disease needing lasting treatment in a lot of patients and in some cases huge amount of topical steroids. Skin degeneration is the most problematic local side result which making complex the long term use topical steroids. It is clinically defined by thinning of the skin, loss of elasticity, loss of skin noting, telangiectasia and purpura. The aim of this study was to perform a literature review to prepare for evidence-based recommendations on the efficacy of topical corticosteroids in psoriasis including treatment modalities to induce remission and prevent recurrence. Methodology: We conducted an electronic search through online databases such; Medline, and Embase, for studies concerning efficacy of topical corticosteroids in psoriasis, using the keywords psoriasis AND corticosteroid. search included all studies published in English language up to 2018, May. and we limited our search to only Human subject articls. Discussion: Psoariasis Psoriasis is an immune-mediated chronic inflammatory disease in which inflammation and cell proliferation could happen over. The immunopathogenesis inclusives a wide variety of signaling actions that can be targeted in order to apply a details restorative impact [5,6].The kinase/ STAT pathway( signal transducers and activators of transcription) and PDE4 (phosphodiesterase-4) include intracellular signal transduction necessary for inflammation to create [7-10].Pan-selectin villains inhibit leukocyte extravasation by influencing the capability of immune cells to roll and migrate, consequently reducing inflammation [11,12].Lastly, the system of action of nonsteroidal
4 International Journal of Scientific & Engineering Research Volume 9, Issue 8, August anti-inflammatory representatives stated in this article are as yet not completely recognized but have been revealed to lower cytokine production and cellular proliferation - the two significant elements of psoriasis immunopathogenesis. Efficacy of topical corticosteroid treatment Topical CS are available in a variety of vehicles and can be identified in order of lowering potency, with 7 courses in the USA and four in the UK, as per Stoughton-Cornell classification (Table 1) [13,14].Various other countries might utilize different classifications systems. These classification systems take into consideration the therapeutic index, a ratio comparing the amount of the agent that causes the therapeutic result to the quantity of the agent that triggers harmful impacts. CS of reduced effectiveness are mainly used on the face, groin, axillary areas, and in infants and youngsters, whereas mid- and higher-potency CS are generally utilized as initial treatment on all other locations in grownups. Superpotent CS are mainly utilized for persistent, cutaneous plaques or lesions on the scalp, hands, and/or soles. When used with care, topical CS could be effective and secure. Daily usage in the induction phase of treatment could cause rapid improvement within 4 weeks in up to 46-56% for potent (e.g. betamethasone dipropionate), and up to 68-89% for superpotent (e.g. clobetasol-17-propionate) CS [15,16].For those patients with less resistant plaque psoriasis, therapy may be initiated with lower strength agents if feasible. For more resistant lesions, standards generally recommend that greatest strength agents be restricted for approximately a maximum of 2 weeks of everyday usage [14,17].The German evidencebased guideline suggests selecting and readjusting the class of CS based on the particular skin site to be treated [15,16].There might be distinctions in efficacy and patient adherence with various prep work of CS. To assist patients dosage their topical therapies, the fingertip system concept or application devices could be utilized [18].In medical technique, potent and superpotent CS are
5 International Journal of Scientific & Engineering Research Volume 9, Issue 8, August usually utilized as preliminary treatment to attain quick resolution of lesions. In patients with extensive psoriasis and/or those whose psoriasis substantially affects their quality of life, topical treatment alone may not suffice, and therapy with phototherapy or systemic therapy, including biologics, must be taken into consideration. Table 1. Corticosteroid classification system[13],[14]. Superpotent Class I USA; Class I UK; Class IV Germany Betamethasone dipropionate glycol 0.05% Clobetasol 17-propionate 0.05% Halobetasol propionate 0.05% High potency Class II/III USA; Class II UK; Class III Germany Amcinonide 0.1% Betamethasone dipropionate 0.05% Desoximetasone 0.25% Diflucortolone valerate 0.1% Fluocinonide 0.05% Halcinonide 0.1% Mometasone furoate 0.1% Ointment Cream Lotion Triamcinolone acetonide 0.5% Moderate potency Class IV/V USA; Class III UK; Class II Germany Betamethasone dipropionate 0.05% Betamethasone valerate 0.1% Clobetasone 17-butyrate 0.05% Desonide 0.05% Desoximetasone 0.05% Fluocinonide 0.025% Hydrocortisone 17-valerate 0.2% Prednicarbate 0.1% Triamcinolone acetonide 0.1% Low potency Class VI/VII USA; Class IV UK; Class I Germany Betamethasone valerate 0.05% Desonide 0.05% Fluocinonide 0.01% Hydrocortisone 1.0%, 2.5% Hydrocortisone acetate 0.5%, 1.0% Prednicarbate 0.05% Triamcinolone acetonide 0.025% Efficacy of topical steroids in the treatment of scalp psoriasis: (Fig. 1)
6 International Journal of Scientific & Engineering Research Volume 9, Issue 8, August Eighteen tests focused on the use of topical steroids for scalp psoriasis [19-22],[23-36].Sixteen were between-patient [19-22],[23-31],[33-35] and 2 were within-patient researches [36],[32].Therapy duration varied from 2 to 8 weeks with the majority of durations being less compared to 6 weeks [37],[19-22],[24-28],[31-34],[36].The number of enlisted patients varied from 42 to 1417 patients inning accordance with the test (mean 395 patients). Standards for success went to the very least 75% enhancement in first psoriasis seriousness in seven trials [19],[20],[22],[24],[25],[28],[34] and at the very least 90% (clear or nearly clear) in seven tests [21], [23], [26], [29], [31], [35],[36].In 4 researches [37],[27],[32],[32],[33] efficiency can not be examined according to the definition of therapy success. An overall of 40-75% patients across studies experienced greater than 75% of preliminary scalp psoriasis renovation and from 43% to 90% experienced greater than 90% first psoriasis improvement as shown in Fig. 1. Figure 1. Efficacy of topical steroids in the treatment of scalp psoriasis [19-22],[23-36]. * The response was defined by the investigators as following: a clear or marked improvement b at least 75% improvement c clear or almost clear d absence of disease or very mild disease
7 International Journal of Scientific & Engineering Research Volume 9, Issue 8, August Abbreviations: CP: clobetasol, BMD: betamethasone dipropionate, DMT: desoximethasone, FLUO: fluocinonide, MO: mometasone, N: number of patients in the topical steroid arm, BMV: betamethasone valerate, AMC: amcinonide; TS: topical steroid assessed Efficacy of topical corticosteroids and frequency of application Senter et al. [39] contrasted once-a-day application utilizing fluocinonide vs. a four-times-a-day application routine for 6 weeks in 55 psoriasis patients. A mean amount of 429 g of fluocinonide was utilized per patient in the four times everyday application group contrasted with 132 g in the when everyday application group. There was no significant difference in between the 2 groups in regards to efficacy. Efficiency of topical steroids as a maintenance treatment for body plaque psoriasis Three studies evaluated the maintenance treatment of body plaque psoriasis with only two providing with maintenance efficiency information[39-41].katz et al. [40] performed an open label screening stage with increased bethametasone dipropionate (ABD) twice daily for 3 or 4 weeks. In responders, 46 patients received ultimately 3 successive applications of ABD 12 h a component, once a week, for 5 months and 44 patients obtained vehicle with the very same routine. At 6 months, 65% of patients treated with ABD stayed in remission vs. 20% of vehicle patients. Lebwhol et al. [41] treated 44 patients with a 2-week run in period with everyday calcipotriene lotion in the morning and halobetasol lotion. Patients who were at least moderately (50% or higher) improved were randomized to get halobetasol ointment two times daily on week-end and calcipotriene ointment two times daily on weekdays (20 patients), or to get halobetasol ointment two times daily on week-end and placebo ointment twice everyday on weekdays (20 patients). Forty percent (n =8) of patients using halobetasol lotion on week-end just with the car on
8 International Journal of Scientific & Engineering Research Volume 9, Issue 8, August weekdays were able to preserve remission for 6 months contrasted with 76% (n =13) of patients using halobetasol ointment on week-end and calcipotriene ointment on weekdays recommending that the enhancement of calcipotriene ointment applied on weekdays to a week-end pulse treatment program of superpotent corticosteroid can enhance the duration of psoriasis remission. Topical steroids as a maintenance treatment for scalp psoriasis The only research study assessing the benefit of a maintenance therapy for scalp psoriasis was released by Poulin et alia [42].In the trial, 212 individuals with moderate-to-severe scalp psoriasis were at first handled with CP( clobetasol propionate) hair shampoo once a day for as much as 4 weeks. Responders were consequently randomized to obtain the CP hair shampoo or vehicle twice weekly on a maintenance program for as much as 6 months. When a regression happened defined as GSS > 2, individuals returned to day-to-day CP shampoo therapy. When the symptoms lessened (GSS < or = 2), they went back to the twice-weekly upkeep routine. After 6 months 31.1% (33 106) of participants in the CP shampoo team were still relapse complimentary, vs. 8.1% (9 111) of participants in the car group (P < 0.01). Safety of topical corticosteroid treatment Topical CS can be related to many prospective unfortunate impacts consisting of cutaneous degeneration, development of telangiectasia, growth of striae, steroid rosacea and perioral dermatitis, hypothalamic-pituitary-adrenal (HPA) axis suppression, skin infections and various other effects. Striae are permanent and difficult to deal with, while telangiectasia and atrophy could be lasting or permanent. The possibility for negative effects is usually linked with extended and/or extensive use of topical CS and typically associates with increased medical strength. The face and the intertriginous locations are particularly conscious these results. Systemic absorption
9 International Journal of Scientific & Engineering Research Volume 9, Issue 8, August of CS could result in laboratory evidence of adrenal reductions, and danger aspects consist of high potency CS, occlusive or long term therapy duration and use in thin-skinned locations.9 Children are extra at risk to these systemic negative effects, because of their smaller body mass in relationship to the surface area included; nonetheless, non-reversible additional adrenal insufficiency has not been recorded [43].Security of topical CS and various other topical treatments has been just recently evaluated [44]. Although topical CS have the possible to cause skin atrophy and short-lived adrenal reductions, it is less clear to just what degree such negative effects happen when topical CS are used in the management of psoriasis. There is generally no medical proof of skin atrophy and limited instances of reversible adrenal reductions when used for brief durations of time [45-50].The risk of skin degeneration raises when CS are used on thin skin such as the face and the intertriginous areas, yet reduced potency CS generally pose much less of an iatrogenic danger. In one research study, no impacts on skin thickness were observed in 30 patients with psoriasis or other forms of facial dermatoses treated with clobetasone butyrate 0.05% ointment for approximately 7 weeks [51].In an additional research study of 20 grownups treated with fluticasone propionate 0.005% ointment twice daily for 2 weeks, after that when day-to-day for two successive days every week for 8 weeks, skin atrophy and telangiectasia did not take place [52]. Cutaneous atrophy was additionally not observed when mometasone furoate 0.1% ointment was used daily to the face and intertriginous areas of 15 psoriasis patients for 2 weeks [53].Extra studies with more patients complied with over much longer amount of times are had to much better understand the effects of these representatives on skin atrophy. Psoriasis is a chronic condition and requires a protracted therapeutic approach, making it challenging to use high-potency topical CS safely in lasting management of the condition.
10 International Journal of Scientific & Engineering Research Volume 9, Issue 8, August Adverse effects of topical CS have been well-documented, and some basic principles should be followed to minimize these impacts (Table 2). The proof for possible therapy regimens exists listed below; nonetheless, some of these usages may be off-label. Table 2.Strategies to improve safety for long-term use of topical corticosteroids. 1.Use treatment regimens that minimize side effects (e.g. weekend only/pulse therapy) 2.Combine topical corticosteroids with other topical agents 3.Follow package insert recommendations 4.Use caution in vulnerable areas (i.e. face, intertriginous or other thin-skinned areas) 5.Use caution in infants and children Conclusion: Topical CS are an essential component of the psoriasis therapeutic apparatus. The outcomes of this existing review indicate that topical steroids in the therapy of adult psoriasis are extremely safe if utilized according to the guidelines. The indication of topical steroids for psoriasis should be limited to mild or moderate psoriasis with much less compared to 10% of body surface location impacted making use of a 4-week daily therapy. The effectiveness of treatment should be assessed within months after the preliminary prescription. While relatively risk-free in the temporary, approaches such as the weekend-only/pulse therapy program or incorporating topical CS with other topical agents may enhance their security profile over longer periods. Caution has to be used when topical CS are applied in vulnerable locations and in infants and youngsters. Extra long-lasting studies of topical corticosteroids are required, ways to detect early damages ought to be checked out, and new topical agents with improved restorative indices should be developed. This examination is vital to prevent misusage and subsequently issues from utilizing topical steroids. Reference:
11 International Journal of Scientific & Engineering Research Volume 9, Issue 8, August Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361: Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58: Castela E, Archier E, Devaux S, et al. Topical corticosteroids in plaquepsoriasis: a systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 3): Bucks DA, Maibach HI, Guy RH. Percutaneous absorption of steroids: effect of repeated application. J Pharm Sci 1985; 74: Nograles KE, Davidovici B, Krueger JG. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg 2010;29: Johnson-Huang LM, McNutt NS, Krueger JG, Lowes MA. Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol 2009;29: Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007;178: Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 2007;8: Sano S, Chan KS, DiGiovanni J. Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases. J Dermatol Sci 2008;50: Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 2007;6: Song H, Wang R, Wang S, Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005;102: Miyoshi K, Takaishi M, Nakajima K, et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol 2011;131: Lebwohl M, Ting PT, Koo JY. Psoriasis treatment: traditional therapy. Ann Rheum Dis 2005; 64(Suppl.): ii Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007; 370: Nast A, Kopp IB, Augustin M et al. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007; 5(Suppl.): Nast A, Kopp I, Augustin M et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2007; 299: Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol 2005; 53: S50 S Bewley A. Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids. Br J Dermatol 2008; 158:
12 International Journal of Scientific & Engineering Research Volume 9, Issue 8, August Olsen EA, Cram DL, Ellis CN et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991; 24: Ellis CN, Horwitz SN, Menter A. Amcinonide lotion 0.1% in the treatment of patients with psoriasis of the scalp. Curr Therapeu Res Clin Exp 1988; 44: Franz TJ, Parsell DA, Halualani RM et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38: Katz HI, Lindholm JS, Weiss JS et al. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Clin Ther 1995; 17: Van de Kerkhof PCM, Hoffmann V, Anstey A et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol 2009; 160: Willis I, Cornell RC, Penneys NS et al. Multicenter study comparing 0.05% gel formulations of desoximetasone and fluocinonide in patients with scalp psoriasis. Clin Ther 1986; 8: VanderPloeg DE, Cornell RC, Binder R et al. Clinical trial in scalp psoriasis mometasone furoate lotion 0.1% apllied once daily vs betamethasone valerate lotion 0.1% applied twice daily. Acta Therapeutica 1989; 15: Reygagne P, Mrowietz U, Decroix J et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat 2005; 16: Pauporte M, Maibach H, Lowe N et al. Fluocinolone acetonide topical oil for scalp psoriasis. J Dermatolog Treat 2004; 15: Klaber MR, Hutchinson PE, Pedvis-Leftick A et al. Comparative effects of calcipotriol solution (50 micrograms ml) and betamethasone 17-valerate solution (1 mg ml) in the treatment of scalp psoriasis. Br J Dermatol 1994; 131: Jemec GBE, Ganslandt C, Ortonne J et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 2008; 59: Jemec GBE, van de Kerkhof PCM, Enevold A et al. Significant one week efficacy of a calcipotriol plus betamethasone dipropionate scalp formulation. J Eur Acad Dermatol Venereol 2011; 25: Jarratt M, Breneman D, Gottlieb AB et al. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004; 3: Jarratt M, Davis JG, Giltner MP, Jones ML, Peets EA. Comparative studies of augmented betamethasone dipropionate lotion 0.05% and clobetasol propionate solution 0.05%:
13 International Journal of Scientific & Engineering Research Volume 9, Issue 8, August correlation of the vasoconstriction assay and clinical activity in scalp psoriasis. Adv Ther 1991; 8: Feldman SR, Ravis SM, Fleischer ABJ et al. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis. J Cutan Med Surg 2001; 5: Duweb GA, Abuzariba O, Rahim M et al. Scalp psoriasis: topical calcipotriol 50 micrograms g ml solution vs. betamethasone valerate 1% lotion. Int J Clin Pharmacol Res 2000; 20: Buckley C, Hoffmann V, Shapiro J et al. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008; 217: Andreassi L, Giannetti A, Milani M. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol 2003; 148: Fredriksson T, Salde L. A double-blind trial of budesonide and betamethasone- 17,21- dipropionate in psoriasis. Curr Med Res Opin 1982; 8: Senter TP, Stimson DH, Charles G et al. Comparison of two therapeutic regimens using the same topical corticoid for stable psoriasis. West J Med 1983; 139: Schmidt H, Hjorth N, Salde L. A double-blind trial of budesonide ointment and betamethasone-17-valerate ointment in psoriasis. J Int Med Res 1981; 9: Katz HI, Prawer SE, Medansky RS et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991; 183: Lebwohl M, Yoles A, Lombardi K et al. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 1998; 39: Poulin Y, Papp K, Bissonnette R et al. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis. Cutis 2010; 85: Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol 2002; 3: van de Kerkhof PC, Barker J, Griffiths CE et al. Psoriasis: consensus on topical therapies. J Eur Acad Dermatol Venereol 2007; 22: Jegasothy B, Jacobson C, Levine N et al. Clobetasol propionate versus fluocinonide creams in psoriasis and eczema. Int J Dermatol 1985; 24: Callen J. Comparison of safety and efficacy of fluticasone propionate cream, 0.05%, and betamethasone valerate cream, 0.1%, in the treatment of moderate-to-severe psoriasis. Cutis 1996; 57: Katz HI, Hien NT, Prawer SE et al. Superpotent topical steroid treatment of psoriasis vulgaris clinical efficacy and adrenal function. J Am Acad Dermatol 1987; 16:
14 International Journal of Scientific & Engineering Research Volume 9, Issue 8, August Katz HI, Gross E, Buxman M et al. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis.j Am Acad Dermatol 1991; 25: Andres P, Poncet M, Farzaneh S et al. Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. J Drugs Dermatol 2006; 5: Beutner K, Chakrabarty A, Lemke S et al. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol 2006; 5: Ishi M, Kohno T, Kitajima JI. Clinical evaluations of clobetasone 17- butyrate ointment on the various facial dermatoses. Skin Res 1986; 28: Lebwohl MG, Tan MH, Meador SL et al. Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 2001; 44: LebwohlM, Peets E, Chen V. Limited application of mometasone furoate on theface and intertriginous areas: analysis of safety and efficacy.int J Dermatol 1993; 32:
Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities
DOI: 10.1111/j.1468-3083.2012.04522.x JEADV REVIEW ARTICLE Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities E. Castela, E. Archier, S. Devaux, A. Gallini,
More informationPharmacologic Treatment of Atopic Dermatitis
J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa
More informationMedication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationThe safety and effectiveness of Dupixent in pediatric patients have not been established (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent
More informationLiterature Scan: Topical Corticosteroids. Month/Year of Review: March 2015 Date of Last Review: March 2013 Source Document: OSU College of Pharmacy
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology is intended for the treatment of: Steroid responsive dermatoses such as psoriasis and seborrheic dermatitis of the hairy regions,
More informationDupixent (dupilumab)
Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationScalp psoriasis is a common inflammatory disease
Short-Contact Clobetasol Propionate Shampoo.5% Improves Quality of Life in Patients With Scalp Psoriasis Jerry Tan, MD, FRCPC; Richard Thomas, MD; Béatrice Wang, MD; David Gratton, MD; Ronald Vender, MD;
More informationUsing Your ESP* in Pharmacy: How to Improve Treatment Adherence and Patient Outcomes in Psoriasis (*Expanded Scope of Practice)
Using Your ESP* in Pharmacy: How to Improve Treatment Adherence and Patient Outcomes in Psoriasis (*Expanded Scope of Practice) Patient Case Study in Psoriasis Patient Case Study in Psoriasis William Smith,
More informationPsoriasis is a lifelong condition, with onset
THERAPEUTICS FOR THE CLINICIAN Clobetasol Propionate Lotion in the Treatment of Moderate to Severe Plaque-Type Psoriasis Jacques Decroix, MD; Henrik Pres, MD; Nicolaï Tsankov, MD; Michel Poncet, PhD; Stéphanie
More informationMonth/Year of Review: January 2015 Date of Last Review: January 2010
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More information50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate).
DUPISOR Composition Gel 50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate). Action Calcipotriol is a non-steroidal antipsoriatic agent, derived from vitamin D. Calcipotriol
More informationTOPCORT Cream/Ointment (Mometasone furoate 0.1%)
Published on: 10 Jul 2014 TOPCORT Cream/Ointment (Mometasone furoate 0.1%) Composition TOPCORT Cream Mometasone Furoate, IP... 0.1% w/w In a cream base... q.s. TOPCORT Ointment Mometasone Furoate, IP...
More information15 minute eczema consultation
THERAPY WORKSHOP 15 minute eczema consultation History Current treatments Examination Treatment Plan Written action plan Soap substitute/bath oil Antiseptic baths Emollients Topical steroids Other treatments
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationDIPROSONE OV Cream and Ointment do not contain preservatives, parabens or lanolin.
PRODUCT INFORMATION DIPROSONE OV (OPTIMISED VEHICLE) CREAM AND OINTMENT NAME OF THE MEDICINE DIPROSONE OV Cream and Ointment (Betamethasone dipropionate) Chemistry Abstracts Service (CAS) registry number:
More informationEFFICACY AND SAFETY OF CLOBETASOL PROPIONATE SHAMPOO IN THERAPY OF PSORIASIS OF THE SCALP
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Platonova et al. SJIF Impact Factor 2.786 Volume 4, Issue 04, 238-246. Research Article ISSN 2278 4357 EFFICACY AND SAFETY OF CLOBETASOL PROPIONATE
More informationTexas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)
Diagnosis: ATOPIC DERMATITIS (AD) Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) PATIENT ADVICE: Unfortunately, there is no cure for atopic dermatitis, so
More informationEach gram of the ointment contains 0.25 mg Fluocinolone Acetonide in a base containing White Petrolatum.
FLUOCINOLONE ACETONIDE- fluocinolone acetonide ointment E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. ---------- FLUOCINOLONE ACETONIDE OINTMENT, USP, 0.025% For Topical Us e Only. Not for
More informationNew Medicine Report. Pimecrolimus. RED- Hospital only Date of Last Revision 6 th March 2003
New Medicine Report Document Status Pimecrolimus Reviewed by Suffolk D&T RED- Hospital only Date of Last Revision 6 th March 2003 Approved Name Pimecrolimus Trade Name Elidel Manufacturer Novartis Legal
More informationHYDROCORTISONE OINTMENT USP,
HYDROCORTISONE- hydrocortisone ointment E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. ---------- HYDROCORTISONE OINTMENT USP, 1% Rx only For External Us e Only Not For Ophthalmic Us e DESCRIPTION:
More informationFor topical use only. Not for oral, ophthalmic, or intravaginal use.
DESOXIMETASONE Ointment USP, 0.25% For topical use only. Not for oral, ophthalmic, or intravaginal use. Rx only DESCRIPTION Desoximetasone ointment USP, 0.25% contains the active synthetic corticosteroid
More informationPrescribing Information
Prescribing Information Pr DERMOVATE Cream (clobetasol propionate cream, USP) Pr DERMOVATE Ointment (clobetasol propionate ointment, USP) Topical corticosteroid TaroPharma Preparation Date: A Division
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Enstilar, Sernivo, Taclonex) Reference Number: CP.CPA.255 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end
More informationAtopic Eczema with detail on how to apply wet wraps
Atopic Eczema with detail on how to apply wet wraps Dr Carol Hlela Consultant Dermatologist Head of Unit, Department of Dermatology, Paediatrics Red Cross Children s Hospital, UCT Red Cross War Memorial
More information75th AAD Annual Meeting
75th AAD Annual Meeting Poster nº 4873 A phase 3 randomized, double-blind, trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064%
More informationPRODUCT INFORMATION ELEUPHRAT CREAM, OINTMENT AND LOTION. Betamethasone dipropionate equivalent to betamethasone 0.5 mg/g (0.
PRODUCT INFORMATION ELEUPHRAT CREAM, OINTMENT AND LOTION NAME OF THE MEDICINE Betamethasone dipropionate equivalent to betamethasone 0.5 mg/g (0.05% w/w) Chemical Structure: Betamethasone dipropionate
More informationPharmacy Benefit Determination Policy
Policy Subject: Atopic Dermatitis Agents Policy Number: SHS PBD18 Category: Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual HMO/POS PPO ASO s:
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review
More informationDermatology elective for yr. 5. Natta Rajatanavin, MD. Div. of dermatology Dep. Of Medicine, Ramathibodi Hospital Mahidol University 23 rd Feb 2015
Dermatology elective for yr. 5 Natta Rajatanavin, MD. Div. of dermatology Dep. Of Medicine, Ramathibodi Hospital Mahidol University 23 rd Feb 2015 How to diagnosis and manage eczema and psoriasis. Objectives
More informationKeywords: Psoriasis vulgaris Zinc pyrithione Betamethasone dipropionate
CLINICAL EFFICACY AND SAFETY OF A COMBINED FORMULATION OF ZINC PYRITHIONE 0.25% AND BETAMETHASONE DIPROPIONATE MICRONIZED 0.05% IN THE TREATMENT OF MILD TO MODERATE PLAQUE PSORIASIS. Abstract Background
More informationPrescribing Information. Taro-Clobetasol. Taro-Clobetasol
Prescribing Information Pr Taro-Clobetasol Clobetasol Propionate Cream USP, 0.05% w/w Pr Taro-Clobetasol Clobetasol Propionate Ointment USP, 0.05% w/w Therapeutic Classification Topical corticosteroid
More informationCordran Cream and Cordran Ointment Flurandrenolide, USP
Cordran Cream and Cordran Ointment Flurandrenolide, USP DESCRIPTION Cordran (flurandrenolide, USP) is a potent corticosteroid intended for topical use. Flurandrenolide occurs as white to off-white, fluffy,
More informationWhat s Topical About Topicals?
What s Topical About Topicals? Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics July 29, 2017 2015 MFMER 3513105-1 Disclosures None 2015 MFMER 3513105-2 Outline Topical steroids
More informationPRODUCT MONOGRAPH ELOCOM. Mometasone Furoate Cream, BP, 0.1% Mometasone Furoate Ointment, Merck Standard, 0.1% Mometasone Furoate Lotion, 0.
PRODUCT MONOGRAPH ELOCOM Mometasone Furoate Cream, BP, 0.1% Mometasone Furoate Ointment, Merck Standard, 0.1% Mometasone Furoate Lotion, 0.1% Topical Corticosteroid Therapy Merck Canada Inc. 16750 route
More informationEnstilar , Version 3 PUBLIC SUMMARY OF RISK MANAGEMENT PLAN
Enstilar 21.1.2016, Version 3 PUBLIC SUMMARY OF RISK MANAGEMENT PLAN VI.2.1 Overview of disease epidemiology Psoriasis is a common skin disease where parts of the skin develop into thick, red and scaly
More informationTopical Immunomodulator Step Therapy Program
Topical Immunomodulator Step Therapy Program Policy Number: 5.01.557 Last Review: 8/2017 Origination: 7/2013 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) BCBSKC will provide
More informationPooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp
DOI: 10.1111/jdv.12444 JEADV ORIGINAL ARTICLE Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp K. Kragballe 1 *, P. van de
More informationFLUOCINOLONE ACETONIDE-
FLUOCINOLONE ACETONIDE- fluocinolone acetonide cream E. & Co. a division of Pharmaceuticals Inc. ---------- FLUOCINOLONE ACETONIDE CREAM, USP 0.01%, 0.025% For Topical Us e Only. Not for Ophthalmic Us
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationTopical Products with Quantity Limits
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Page: 1 of 8 Last Review Date: November 30, 2018 Description Apexicon E Topical Cream 0.05% (diflorasone
More informationDATA SHEET. Betamethasone dipropionate equivalent to betamethasone 0.5mg/g (0.05% w/w).
DATA SHEET 1. DIPROSONE DIPROSONE (0.05% w/w) cream DIPROSONE (0.05% w/w) ointment 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Betamethasone dipropionate equivalent to betamethasone 0.5mg/g (0.05% w/w).
More informationPRODUCT MONOGRAPH. Taro-Mometasone Cream (Mometasone Furoate Cream, USP) 0.1% (w/w)
PRODUCT MONOGRAPH Pr Taro-Mometasone Cream (Mometasone Furoate Cream, USP) 0.1% (w/w) Pr Taro-Mometasone Ointment (Mometasone Furoate Ointment, USP) 0.1% (w/w) Pr Taro-Mometasone Lotion (Mometasone Furoate
More informationManaging and Minimizing Flare-ups in Atopic Dermatitis
Managing and Minimizing Flare-ups in Atopic Dermatitis Importance of the skin barrier & how commonly used drugs are impacting it Dr. Benjamin Barankin, MD FRCPC Medical Director & Founder of Toronto Dermatology
More informationRELEVANT DISCLOSURES ATOPIC DERMATITIS / ECZEMA MANAGING ECZEMA IN INFANTS AND CHILDREN
RELEVANT DISCLOSURES MANAGING ECZEMA IN INFANTS AND CHILDREN Advisory board member - MEDA (Elidel), Speaking honoraria Bayer (Advantan) Advisory board, consultant, speaker: Pfizer, Abbvie, Janssen, Elli
More informationCOMPARATIVE STUDY OF THE EFFICACY OF VARIOUS TOPICAL TREATMENT MODALITIES AND PHOTOTHERAPY FOR PSORIASIS VULGARIS: A REVIEW
COMPARATIVE STUDY OF THE EFFICACY OF VARIOUS TOPICAL TREATMENT MODALITIES AND PHOTOTHERAPY FOR PSORIASIS VULGARIS: A REVIEW Dr. Shweta Aryal *, Prof. Dr. Liu Jin Xian, Dr. Gong Shao Zhi and Dr. Jyoti Karki
More informationThis PDF is available for free download from a site hosted by Medknow Publications
Net Study Comparison of clinical efficacy of topical tazarotene.1% cream with topical clobetasol propionate.5% cream in chronic plaque psoriasis: A double-blind, randomized, right-left comparison study
More informationPRESCRIBING INFORMATION. ratio-topisone. Betamethasone dipropionate USP. 0.5 mg Cream, Ointment and Lotion. Topical corticosteroid
PRESCRIBING INFORMATION ratio-topisone Betamethasone dipropionate USP 0.5 mg Cream, Ointment and Lotion Topical corticosteroid Teva Canada Limited Date of Revision 30 Novopharm Court January 21, 2013 Toronto,
More informationFluocinolone Acetonide 0.01% Topical Oil (Scalp Oil)
Fluocinolone Acetonide 0.01% Topical Oil (Scalp Oil) For Topical Use Only- Not for Oral, Ophthalmic, or Intravaginal Use DESCRIPTION Fluocinolone Acetonide 0.01% Topical Oil contains fluocinolone acetonide
More informationChemically, clobetasol propionate is 21-chloro-9-fluoro,11β,17-dihydroxy-16βmethylpregna-1,4-diene-3,20-dione
Clobetasol Propionate Cream USP, 0.05% FOR TOPICAL DERMATOLOGIC USE ONLY NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE. DESCRIPTION Clobetasol propionate cream USP, 0.05% contain the active compound clobetasol
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Flutarzole 0,05% w/w cream, Fluticasone propionate
PACKAGE LEAFLET: INFORMATION FOR THE USER Flutarzole 0,05% w/w cream, Fluticasone propionate 1. IDENTIFICATION OF THE MEDICINAL PRODUCT 1.1. Trade name Flutarzole 1.2. Composition Active substance: Fluticasone
More informationTopical long-term therapy of psoriasis with vitamin D 3
Review Article Submitted: 9.5.2014 Accepted: 12.5.2014 DOI: 10.1111/ddg.12396 Topical long-term therapy of psoriasis with vitamin D 3 analogues, corticosteroids and their two compound formulations: position
More informationPsoriasis is an inflammatory condition of the skin that
Mayo Clin Proc, September 2001, Vol 76 Topical Therapies for Localized Psoriasis 943 Concise Review for Clinicians Concise Review for Clinicians Topical Therapies for Localized Psoriasis PATRICIA M. WITMAN,
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Psoriasis (excluding widespread plaque psoriasis) Psoriasis is a common chronic skin disorder. Estimates of the prevalence (proportion
More informationDIPROLENE AF (augmented betamethasone dipropionate) Cream, 0.05% for topical use Initial U.S. Approval: 1983
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DIPROLENE AF Cream safely and effectively. See full prescribing information for DIPROLENE AF Cream.
More informationSteroid use in managing your child s Atopic Eczema
Steroid use in managing your child s Atopic Eczema Clinical Nurse Specialist for Paediatric Dermatology (01284) 713575 Step up step down approach: Addressograph Severe Call your General Practitioner (GP)
More informationThe role of current biologic therapies in psoriasis
: An Update on and IL-17 Inhibitors Joanna Dong, BA; Gary Goldenberg, MD PRACTICE POINTS The newest biologics for treatment of moderate to severe plaque psoriasis are and IL-17 inhibitors with unprecedented
More informationKEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality.
KEY MESSAGES Psoriasis is a genetically determined, systemic immune-mediated chronic inflammatory disease that affects primarily the skin and joints. Psoriasis Vulgaris is characterised by well-demarcated
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dupixent) Reference Number: CP.HNMC.208 Effective Date: 04.11.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationRevised: 03/2018. *Sections or subsections omitted from the full prescribing information are not listed.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DIPROLENE Ointment safely and effectively. See full prescribing information for DIPROLENE Ointment.
More informationVitiligo is a skin depigmentation disorder
THERPEUTICS FOR THE CLINICIN Tacrolimus Ointment 0.1% Produces Repigmentation in Patients With Vitiligo: Results of a Prospective Patient Series Emil. Tanghetti, MD The cause of the selective melanocyte
More informationCatherine Queille-Roussel Martin Olesen John Villumsen Jean-Philippe Lacour
Clin Drug Investig (2015) 35:239 245 DOI 10.1007/s40261-015-0269-7 ORIGINAL RESEARCH ARTICLE Efficacy of an Innovative Aerosol Foam Formulation of Fixed Combination Calcipotriol plus Betamethasone Dipropionate
More informationNOVASONE CREAM, OINTMENT AND LOTION PRODUCT INFORMATION
NAME OF THE MEDICINE Mometasone furoate 0.1% (1 mg/g) Chemical structure: NOVASONE CREAM, OINTMENT AND LOTION PRODUCT INFORMATION Mometasone furoate is 9,21-dichloro-11ß,17-dihydroxy-16 -methylpregna-1,4-diene-
More informationJEADV ORIGINAL ARTICLE. Abstract
DOI: 1.1111/jdv.1323 JEADV ORIGINAL ARTICLE Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the
More informationDrug Class Literature Scan: Topical Steroids
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 03/2018
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DIPROLENE Lotion safely and effectively. See full prescribing information for DIPROLENE Lotion. DIPROLENE
More informationPsoriasis. Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center
Psoriasis Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center Learning objectives Recognize the different types of psoriasis
More informationHydroVal (Hydrocortisone Valerate)
PRODUCT MONOGRAPH HydroVal (Hydrocortisone Valerate) Cream & Ointment 0.2 % Topical Corticosteroid TaroPharma Preparation Date: A Division of Taro Pharmaceuticals Inc. Sept 02, 2003 130 East Drive Brampton,
More informationTopical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence
Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence Linda F. Stein Gold, MD* n Abstract Psoriasis is a chronic disease that has a substantial effect on quality of life
More informationZatamil. Mometasone furoate PRODUCT INFORMATION
Zatamil Mometasone furoate PRODUCT INFORMATION NAME OF THE MEDICINE Mometasone furoate 0.1% (1 mg/g) Chemical Structure: CAS No. 83919-23-7 Molecular weight: 521.4 Mometazone furoate is 9α,21-dichloro-11β,17-dihydroxy-16α-methylpregna-1,4-diene-3,20-
More informationThe active ingredient of any pharmaceutical
Close Encounters With the Environment Stratum Corneum Absorption Kinetics of 2 Potent Topical Corticosteroid Formulations: A Pilot Study Zoe Diana Draelos, MD Practice Points Fluocinonide concentration
More informationPRODUCT MONOGRAPH DIPROLENE. Glycol OINTMENT/CREAM/LOTION (betamethasone dipropionate 0.05% W/W) Topical Corticosteroid
PRODUCT MONOGRAPH DIPROLENE Glycol OINTMENT/CREAM/LOTION (betamethasone dipropionate 0.05% W/W) Topical Corticosteroid Merck Canada Inc. DATE OF REVISION: 16750 route Transcanadienne Kirkland, QC Canada
More informationAn Efficacy Study of 3 Commercially Available Hydroquinone 4% Treatments for Melasma
An Efficacy Study of 3 Commercially Available Hydroquinone 4% Treatments for Melasma Pearl E. Grimes, MD Melasma is a common disorder of hyperpigmentation typically characterized by relatively symmetric
More informationCLINICAL PHARMACOLOGY
ELOCON brand of mometasone furoate ointment Ointment 0.1% For Dermatologic Use Only Not for Ophthalmic Use DESCRIPTION ELOCON (mometasone furoate ointment) Ointment, 0.1%, contains mometasone furoate,
More informationComparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis
Original Article Comparative efficacy of topical mometasone furoate 0.1% cream vs topical tacrolimus 0.03% ointment in the treatment of atopic dermatitis Md Alauddin Khan *, Lubna Khondker **, Dilshad
More informationComparison of representative topical corticosteroid preparations (classified according to the US system)
Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),
More informationTopical Corticosteroids
Topical Corticosteroids Topical Cοrt cοsterοids Editors Howard L Maibach, San Francisco, Calif. Christian Surber, Basel 83 figures and 91 tables, 1992 KARG E R. Basel München Paris London NewYork New
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ovixan 1 mg/g cream 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram cream contains 1 mg mometasone furoate Excipients with known
More informationPRODUCT MONOGRAPH. Mometasone Furoate 0.1% Ointment, USP. Topical Corticosteroid
PRODUCT MONOGRAPH Pr TEVA-MOMETASONE Mometasone Furoate 0.1% Ointment, USP Topical Corticosteroid Teva Canada Limited 30 Novopharm Court Toronto, Canada M1B 2K9 www.tevacanada.com Date of Revision: May
More informationRelative Efficacy and Interchangeability of Various Clobetasol Propionate Vehicles in the Management of Steroid-Responsive Dermatoses
VLUM 66, NUMBR 3, MAY/JUN 25 Review Article Relative fficacy and Interchangeability of Various Clobetasol Propionate Vehicles in the Management of Steroid-Responsive Dermatoses Steven R. Feldman, MD, PhD
More informationPRODUCT MONOGRAPH DIPROSONE. Betamethasone Dipropionate Cream, Merck Standard, 0.05% W/W betamethasone (as dipropionate)
PRODUCT MONOGRAPH DIPROSONE Betamethasone Dipropionate Cream, Merck Standard, Betamethasone Dipropionate Ointment, Merck Standard, Betamethasone Dipropionate Lotion, USP, Topical Corticosteroid Merck Canada
More informationAtopic dermatitis: tacrolimus vs. topical corticosteroid use
Atopic dermatitis: tacrolimus vs. topical corticosteroid use Langa Y, BPharm Van der Merwe E, BPharm, MSc (Pharmacology) Correspondence to: Elsabe van der Merwe, e-mail: elsabev@medikredit.co.za Keywords:
More informationUltravate (halobetasol propionate) Cream, 0.05% (halobetasol propionate) Ointment, 0.05% For Dermatological Use Only. Not for Ophthalmic Use.
Ultravate (halobetasol propionate) Cream, 0.05% (halobetasol propionate) Ointment, 0.05% For Dermatological Use Only. Not for Ophthalmic Use. Rx only DESCRIPTION Ultravate contains halobetasol propionate,
More informationPRESCRIBING INFORMATION. Cream 0.025% Topical Corticosteroid
PRESCRIBING INFORMATION Pr PROPADERM (beclomethasone dipropionate) Cream 0.025% Topical Corticosteroid Valeant Canada LP 2150 St-Elzear Blvd. West, Laval, Quebec, Canada H7L 4A8 Date of preparation: October
More informationAtopic dermatitis Tacrolimus vs topical corticosteroid use
Atopic dermatitis Tacrolimus vs topical corticosteroid use Yolande Langa, BPharm Elsabé van der Merwe, BPharm; MSc (Pharmacology) Abstract Atopic dermatitis (AD), the dermatologic manifestation of the
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory TENOVATE TM. Clobetasol Cream IP/ Clobetasol Ointment IP
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory TENOVATE TM Clobetasol Cream IP/ Clobetasol Ointment IP QUALITATIVE AND QUANTITATIVE COMPOSITION TENOVATE Cream contains:
More informationSTUDY. 1% Pimecrolimus, 0.005% Calcipotriol, and 0.1% Betamethasone in the Treatment of Intertriginous Psoriasis
STUDY 1% Pimecrolimus, 0.005% Calcipotriol, and 0.1% Betamethasone in the Treatment of Intertriginous Psoriasis A Double-blind, Randomized Controlled Study Alexander Kreuter, MD; Anna Sommer, MD; Julia
More informationCONTRAINDICATIONS None (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use IMPOYZ Cream safely and effectively. See full prescribing information for IMPOYZ Cream. IMPOYZ (clobetasol
More informationProvide relief with Topicort 0.05% 1,2. For your patients with corticosteroid-responsive dermatoses... IMPORTANT SAFETY INFORMATION
For your patients with corticosteroid-responsive dermatoses... SPREAD THE Provide relief with Topicort 0.05% 1,2 Group C molecule 3 Low allergenic potential 4-6 Available in cream and ointment 3,7 Topicort
More informationCorticosteroid contact allergy - the importance of late readings and testing with corticosteroids used by the patients.
Corticosteroid contact allergy - the importance of late readings and testing with corticosteroids used by the patients. Isaksson, Marléne Published in: Contact Dermatitis DOI: 10.1111/j.1600-0536.2007.00959.x
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Technology Appraisals and Guidance Information Services Static List Review (SLR) report Title and TA publication number of static topic: Final decision:
More informationStudy of prescribing pattern of topical corticosteroids in dermatology out patients department in a Tertiary Care Hospital in Puducherry
Manju et al / International Journal of Pharmacological Research 2018; 8(1): 01-05. 1 International Journal of Pharmacological Research ISSN: 2277-3312 (Online) Journal DOI: https://doi.org/10.7439/ijpr
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Excipient with known effect Cetyl alcohol For the full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Haelan Ointment Fludroxycortide 0.0125% w/w Ointment 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Fludroxycortide 0.0125% w/w. Excipient
More informationFollow this and additional works at: Part of the Medicine and Health Sciences Commons
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Is High Dose Intramuscular Alefacept
More informationCOMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of
COMMTTEE OF EXPERTS ON THE CLASSFCATON OF MEDCNES AS REGARDS THER SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group D07 (Corticosteroids, Dermatological
More informationA study of treatment modalities in psoriasis in dermatology outpatient department of a tertiary care teaching hospital
Original article A study of treatment modalities in psoriasis in dermatology outpatient department of a tertiary care teaching hospital 1Y Roja Ramani, 2 Benu Panigrahy, 3 Sailenkumar Mishra, 4 BTPS Singh
More information